RT Journal Article
SR Electronic
T1 Time Windows Voting Classifier for COVID-19 Mortality Prediction
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.02.21259934
DO 10.1101/2021.07.02.21259934
A1 Goh, Tiong-Thye
A1 Liu, MengJun
YR 2021
UL http://medrxiv.org/content/early/2021/07/07/2021.07.02.21259934.abstract
AB Background The ability to predict COVID-19 patients’ level of severity (death or survival) enables clinicians to prioritise treatment. Recently, using three blood biomarkers, an interpretable machine learning model was developed to predict the mortality of COVID-19 patients. The method was reported to be suffering from performance stability because the identified biomarkers are not consistent predictors over an extended duration.Methods To sustain performance, the proposed method partitioned data into three different time windows. For each window, an end-classifier, a mid-classifier and a front-classifier were designed respectively using the XGboost single tree approach. These time window classifiers were integrated into a majority vote classifier and tested with an isolated test data set.Results The voting classifier strengthens the overall performance of 90% cumulative accuracy from a 14 days window to a 21 days prediction window.Conclusions An additional 7 days of prediction window can have a considerable impact on a patient’s chance of survival. This study validated the feasibility of the time window voting classifier and further support the selection of biomarkers features set for the early prognosis of patients with a higher risk of mortality.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementNOAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NA Note: for (3) below, we only use the data set provided in https://www.nature.com/articles/s42256-020-0180-7#Sec10 we do not have any interactions with patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata set can be obtained from https://www.nature.com/articles/s42256-020-0180-7#Sec10 https://www.nature.com/articles/s42256-020-0180-7#Sec10